DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Seven Eight Capital LP

Seven Eight Capital LP boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 825.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,225 shares of the medical device company’s stock after acquiring an additional 42,123 shares during the period. DexCom accounts for about 0.6% of Seven Eight Capital LP’s holdings, making the stock its 18th biggest position. Seven Eight Capital LP’s holdings in DexCom were worth $5,354,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the 2nd quarter valued at about $25,000. Sachetta LLC raised its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. DSM Capital Partners LLC purchased a new position in shares of DexCom in the fourth quarter valued at $28,000. Crewe Advisors LLC acquired a new stake in DexCom in the 1st quarter valued at about $29,000. Finally, Riverview Trust Co purchased a new position in DexCom during the 1st quarter valued at about $32,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DXCM shares. Morgan Stanley dropped their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. UBS Group dropped their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Wells Fargo & Company reduced their target price on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. Royal Bank of Canada dropped their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Finally, Redburn Atlantic initiated coverage on shares of DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Insiders have sold 2,483 shares of company stock valued at $201,708 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 1.6 %

Shares of NASDAQ DXCM opened at $68.94 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock’s 50-day simple moving average is $80.70 and its 200-day simple moving average is $110.54. The firm has a market cap of $27.42 billion, a price-to-earnings ratio of 44.48, a PEG ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.34 EPS. As a group, equities analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.